Multivessel versus culprit lesion only percutaneous revascularization plus potential staged revascularization in patients with acute myocardial infarction complicated by cardiogenic shock: Design and rationale of CULPRIT-SHOCK trial

作者：Thiele Holger^*; Desch Steffen; Piek Jan J; Stepinska Janina; Oldroyd Keith; Serpytis Pranas; Montalescot Gilles; Noc Marko; Huber Kurt; Fuernau Georg; de Waha Suzanne; Meyer Saraei Roza; Schneider Steffen; Windecker Stephan; Savonitto Stefano; Briggs Andrew; Torremante Patrizia; Vrints Christiaan; Schuler Gerhard; Ceglarek Uta; Thiery Joachim; Zeymer Uwe

来源：American Heart Journal, 2016, 172: 160-169.

DOI：10.1016/j.ahj.2015.11.006

Background In acute myocardial infarction complicated by cardiogenic shock (CS), up to 80% of patients present with multivessel coronary artery disease. Currently, the best revascularization strategy is unknown. Therefore, a prospective randomized adequately powered clinical trial is warranted.
Study design The CULPRIT-SHOCK study is a 706-patient controlled, international, multicenter, randomized, open-label trial. It is designed to compare culprit lesion only percutaneous coronary intervention (PCI) with possible staged nonculprit lesion revascularization versus immediate multivessel PCI in patients with CS complicating acute myocardial infarction. Patients will be randomized in a 1:1 fashion to one of the two treatment arms. The primary efficacy endpoint of CULPRIT-SHOCK is 30-day mortality and severe renal failure requiring renal replacement therapy. Secondary outcome measures such as hemodynamic, laboratory, and clinical parameters will serve as surrogate endpoints for prognosis. Furthermore, an intermediate- and long-term follow-up at 6 and 12 months will be performed. Safety endpoints include the assessment of bleeding and stroke.
Conclusions The CULPRIT-SHOCK trial will address the question of optimal revascularization strategy in patients with multivessel disease and acute myocardial infarction complicated by CS.

• 出版日期2016-2